$17.61
0.34% today
Nasdaq, Feb 28, 05:18 pm CET
ISIN
US45781M1018
Symbol
INVA

Innoviva Stock price

$17.55
-1.43 7.53% 1M
-1.56 8.16% 6M
+0.20 1.15% YTD
+2.18 14.18% 1Y
-1.66 8.64% 3Y
+4.05 30.00% 5Y
-0.51 2.82% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.35 1.96%
ISIN
US45781M1018
Symbol
INVA
Sector
Industry

Key metrics

Market capitalization $1.10b
Enterprise Value $1.14b
P/E (TTM) P/E ratio 83.89
EV/FCF (TTM) EV/FCF 6.04
EV/Sales (TTM) EV/Sales 3.05
P/S ratio (TTM) P/S ratio 2.95
P/B ratio (TTM) P/B ratio 1.59
Revenue growth (TTM) Revenue growth 14.88%
Revenue (TTM) Revenue $372.51m
EBIT (operating result TTM) EBIT $166.87m
Free Cash Flow (TTM) Free Cash Flow $188.42m
Cash position $412.50m
EPS (TTM) EPS $0.21
P/E forward 10.44
P/S forward 3.17
EV/Sales forward 3.71
Short interest 27.74%
Show more

Is Innoviva a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Innoviva Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Innoviva forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a Innoviva forecast:

Buy
50%
Hold
50%

Financial data from Innoviva

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
373 373
15% 15%
100%
- Direct Costs 76 76
2% 2%
21%
296 296
20% 20%
79%
- Selling and Administrative Expenses 76 76
21% 21%
20%
- Research and Development Expense 14 14
60% 60%
4%
207 207
38% 38%
55%
- Depreciation and Amortization 40 40
12% 12%
11%
EBIT (Operating Income) EBIT 167 167
47% 47%
45%
Net Profit 23 23
87% 87%
6%

In millions USD.

Don't miss a Thing! We will send you all news about Innoviva directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Innoviva Stock News

Neutral
Business Wire
2 days ago
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the fourth quarter and full ye...
Positive
Seeking Alpha
5 days ago
Innoviva's strong balance sheet and stable royalty income from GlaxoSmithKline provide a solid foundation for its shift to specialty therapeutics, presenting an asymmetric risk-reward profile. The company is transitioning from a royalty collector to an operator in specialty therapeutics, with significant growth in product sales, notably GIAPREZA and XACDURO. Key assets like Zevtera, an advanced...
Neutral
Business Wire
22 days ago
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will p...
More Innoviva News

Company Profile

Innoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Head office United States
CEO Pavel Raifeld
Employees 127
Founded 1996
Website www.inva.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today